Detailed Information on Publication Record
2020
Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450
NEKVINDOVA, J., A. MRKVICOVA, V. ZUBANOVA, A.H. VACULOVA, P. ANZENBACHER et. al.Basic information
Original name
Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450
Authors
NEKVINDOVA, J., A. MRKVICOVA, V. ZUBANOVA, A.H. VACULOVA, P. ANZENBACHER, P. SOUCEK, Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), J. VONDRACEK, A. SPICAKOVA, Lucia BOHOVICOVÁ (203 Czech Republic, belonging to the institution), P. FABIAN, Z. KALA and V. PALICKA
Edition
Biochemical Pharmacology, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2020, 0006-2952
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.858
RIV identification code
RIV/00216224:14740/20:00118001
Organization unit
Central European Institute of Technology
UT WoS
000541248000005
Keywords in English
Hepatocellular carcinoma; Cytochrome P450; CYP; Drug metabolism; Gene expression; Non-coding RNA
Tags
International impact, Reviewed
Změněno: 25/1/2021 10:34, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Hepatocellular carcinoma (HCC) remains a highly prevalent and deadly disease, being among the top causes of cancer-related deaths worldwide. Despite the fact that the liver is the major site of biotransformation, studies on drug metabolizing enzymes in HCC are scarce. It is known that malignant transformation of hepatocytes leads to a significant alteration of their metabolic functions and overall deregulation of gene expression. Advanced stages of the disease are thus frequently associated with liver failure, and severe alteration of drug metabolism. However, the impact of dysregulation of metabolic enzymes on therapeutic efficacy and toxicity in HCC patients is largely unknown. Here we demonstrate a significant down-regulation in European Caucasian patients of cytochromes P450 (CYPs), the major xenobiotic-metabolizing enzymes, in HCC tumour samples as compared to their surrounding non-cancerous (reference) tissue. Moreover, we report for the first time the association of the unique CYP profiles with specific transcriptome changes, and interesting correlations with expression levels of nuclear receptors and with the histological grade of the tumours. Integrated analysis has suggested certain co-expression profiles of CYPs with lncRNAs that need to be further characterized. Patients with large tumours with down-regulated CYPs could be more vulnerable to drug toxicity; on the other hand, such tumours would eliminate drugs more slowly and should be more sensitive to pharmacotherapy (except in the case of pro-drugs where activation is necessary).